The evaluation of effect of ivermectin in addition to standard COVID-19 treatment in intubated patients
Keywords:
Covid-19, Intubation, Ivermectin, Treatment OutcomeAbstract
Introduction: Since the introduction of the Corona pandemic, the use of appropriate antivirals with minimal side effects has been the most important research topic. Laboratory evidence has shown that ivermectin, which has long been available as an anti-parasitic drug market, has anti-COVID19 properties. Therefore, in this study, we investigated the outcomes of this agent administration in patients undergoing mechanical ventilation. Material and method: Intubated patients with Covid 19 who were eligible for the study were randomly divided into two groups: 1) ivermectin recipient (n = 31) and 2) placebo group (n = 29). This study was performed in Center Corona hospitals in Ahvaz from March 2020 to September 2021. Mortality event was Primary outcome; vital signs and pulmonary Compliance were as secondary outcomes of the study. Results: The results of the study did not show a significant difference between the two groups in demographic data including: age, sex, and time of intubation after the onset of symptoms, plasma levels of LDH, ESR, CRP, D-Dimer and IL-6. Survival analysis did not show a significant difference between the mortality event in the two groups.
Downloads
References
Hariyanto, T.I., et al., Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies. 2022. 32(2): p. e2265.
Low, Z.Y., A.J.W. Yip, and S.K.J.B.e.B.A.-M.B.o.D. Lal, Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication. 2022. 1868(2): p. 166294.
Ahmed, S., et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. 2021. 103: p. 214-216.
Babalola, O.E., et al., Ivermectin shows clinical benefits in mild to moderate COVID19: a randomized controlled double-blind, dose-response study in Lagos. 2021. 114(11): p. 780-788.
Reis, G., et al., Effect of early treatment with ivermectin among patients with Covid-19. 2022. 386(18): p. 1721-1731.
Lim, S.C.L., et al., Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: The I-TECH randomized clinical trial. 2022. 182(4): p. 426-435.
Alghamdi A, Ibrahim A, Almutairi R, Joseph M, Alghamdi G, Alhamza A. A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: Male versus female outcomes. Journal of Advanced Pharmacy Education & Research| Apr-Jun. 2021;11(2):51-56
Siyal FJ, Shaikh ZA, Ahmed SZ, Shahid MA, Agha F, Khoso M, Unar AA, Unar K, Saleem R, Shahani MP. Anxiety among COVID-19 physicians during the pandemic in the health care center of the rural region. Archives of Pharmacy Practice. 2020 Oct 1;11(4):91-3.
Magomedova UG, Khadartseva ZA, Grechko VV, Polivanova MN, Mishvelov AE, Povetkin SN, Demchenkov EL, Shevchenko YS. The role of Covid-19 in the acute respiratory pathology formation in children. Pharmacophore. 2020 Sep 1;11(5):61-5.
Fox, L.M.J.C.o.i.i.d., Ivermectin: uses and impact 20 years on. 2006. 19(6): p. 588-593.
Aroke, D., et al., Ivermectin induced Steven–Johnsons syndrome: case report. 2017. 10(1): p. 1-4.
Okumuş, N., et al., Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients. 2021. 21(1): p. 1-11.
Cummings, M.J., et al., Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020. 395(10239): p. 1763-1770.
Konjević, G., et al., Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. 2001. 66(3): p. 255-263.
Wagstaff, K.M., et al., Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. 2012. 443(3): p. 851-856.
Caly, L., et al., The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. 2020. 178: p. 104787.
Chachar, A.Z.K., et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. 2020. 9(09): p. 31-5.
Chowdhury, A., et al., A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. 2021. 5(1): p. 63-70.
Bukhari, K.H.S., et al., Efficacy of ivermectin in COVID-19 patients with mild to moderate disease. 2021.
Ottesen, E.A. and W.J.J.o.a.c. Campbell, Ivermectin in human medicine. 1994. 34(2): p. 195-203.
Rothova, A., et al., Side-effects of ivermectin in treatment of onchocerciasis. 1989. 333(8652): p. 1439-1441.
Richard‐Lenoble, D., et al., Ivermectin and filariasis. 2003. 17(2): p. 199-203.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
